Great Lakes NeuroTechnologies has been awarded a new patent for its technology that quantifies the severity of movement disorders in Parkinson’s disease patients.
Great Lakes’ Kinesia movement disorder assessment technology uses a ring-like sensor worn on a patient’s finger to measure motor symptoms and wirelessly transmit data to physicians on the severity of a patient’s tremors.
Behavioral Health, Interoperability and eConsent: Meeting the Demands of CMS Final Rule Compliance
In a webinar on April 16 at 1pm ET, Aneesh Chopra will moderate a discussion with executives from DocuSign, Velatura, and behavioral health providers on eConsent, health information exchange and compliance with the CMS Final Rule on interoperability.
The newly issued patents cover various aspects of the patient-worn device as well as the technology that processes and transmits movement disorder data, according to a statement from Valley View, Ohio-based Great Lakes.
The idea behind the company’s movement disorder assessment system is that understanding the type and severity of tremors, slowed movements and medication side effects a patient experiences will help doctors better prescribe medications to minimize the patient’s fluctuations throughout the course of a day.
Earlier this year, Great Lakes secured $4.5 million in grant funding through the National Institutes of Health’s Small Business Innovation Research (SBIR) program.
The company is conducting a study of 60 patients with essential tremor, a type of involuntary shaking of the body, as they conduct their daily lives in their homes.
A Deep-dive Into Specialty Pharma
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
Great Lakes is also planning a study that would assess its technology in helping surgeons and neurologists fine-tune deep brain stimulation (DBS) systems after they’ve been implanted in Parkinson’s patients.
